IPS Pharma

IPS Pharma is an independent international pharmaceutical services company founded in 2009, headquartered in the United Kingdom. The company operates in three main areas: Unlicensed medicines (Unlicensed Imports and Specials), Clinical Trials and Special Obtains. IPS Pharma is a leader in pharmaceutical manufacturing, capable of delivering over 20,000 formulations for unlicensed medicines, Investigational Medical Product (IMP), and comparators for clinical trials from its state-of-the-art facility in Surrey. Audited and licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) and a member of the Association of Pharmaceuticals Unlicensed Medicines Manufacturers (APSM), the company ensures the highest standards of practice are followed at all times. With a focus on PRECISELY MEETING PATIENTS’ NEEDS, IPS Pharma is dedicated to improving patients’ quality of life through close collaboration with healthcare professionals, research organizations, and suppliers. IPS Pharma's last investment was a debt financing investment at 10 May 2010, with the investor being Clydesdale Bank. The company operates in the industries of Biotechnology, Manufacturing, and Pharmaceutical. With its commitment to meeting patients' specific needs, continuous investment in manufacturing, technology, and people, IPS Pharma is poised to make a significant impact in the pharmaceutical services sector.